Clinical trials: sponsored by ImmunityBio, Inc.
Advanced Solid Tumors
Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors
This is a phase 1 open-label study to investigate the pharmacokinetics of aldoxorubicin administered as a 30 minute infustion every 3 weeks for up to 8 cycles in subjects with advanced solid tumors.
- Trial name
- NCT01706835
- Testing
- aldoxorubicin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- ImmunityBio, Inc.
Malignant Solid Tumour
Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid Tumors
This is a phase 1b open-label study evaluating the preliminary safety and maximum tolerated dose of a new formulation of INNO-206 administered at doses of 230 mg/m2, 350 mg/m2 and 450 mg/m2 (165, 260, 325 mg/m2 doxorubicin…
- Trial name
- NCT01337505
- Testing
- INNO-206
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- ImmunityBio, Inc.
Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent
QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with advanced, unresectable, and untransplantable HCC.
- Trial name
- NCT03563170
- Testing
- ETBX-011, GI-4000, haNK for infusion
- Where
- United States
- Sponsor
- ImmunityBio, Inc.